Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack.
Yongjun WangYue-Song PanHao LiPierre AmarencoHans DenisonScott R EvansAnders HimmelmannStefan K JamesMikael KnutssonPer LadenvallCarlos A MolinaS Claiborne JohnstonPublished in: Neurology (2022)
This study provides Class II evidence that, for patients with mild-moderate ischemic stroke or high-risk TIA, the ischemic benefit of ticagrelor-aspirin outweighs the risk of major hemorrhage throughout the 30-day treatment period.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- low dose
- cerebral ischemia
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- cardiovascular events
- ischemia reperfusion injury
- coronary artery disease
- high intensity
- type diabetes
- subarachnoid hemorrhage
- oxidative stress
- blood brain barrier
- combination therapy